Cerenis Therapeutics Share Price CINNOBER BOAT
Equities
0RAG
FR0012616852
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
06-14 | Abionyx: positive response from FDA, share price rises | CF |
06-13 | ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis | CI |
Sales 2024 * | 4.6M 4.93M 390M | Sales 2025 * | 7.1M 7.6M 602M | Capitalization | 37.49M 40.15M 3.18B |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.43M -509M | Net income 2025 * | -9M -9.64M -763M | EV / Sales 2024 * | 7.76 x |
Net cash position 2024 * | 1.8M 1.93M 153M | Net Debt 2025 * | 200K 214K 16.95M | EV / Sales 2025 * | 5.31 x |
P/E ratio 2024 * |
-6.85
x | P/E ratio 2025 * |
-5.54
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.84% |
Managers | Title | Age | Since |
---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
Director of Finance/CFO | - | 30/04/08 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 08/02/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 05/02/15 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 31/12/06 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- ABNX Stock
- 0RAG Stock